Bao Jingying, Chen Zhenqian, Li Yu, Chen Long, Wang Wei, Sheng Chunquan, Dong Guoqiang
School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, China.
ACS Med Chem Lett. 2023 Dec 29;15(1):29-35. doi: 10.1021/acsmedchemlett.3c00161. eCollection 2024 Jan 11.
The autophagy-tethering compound (ATTEC) technology has emerged as a promising strategy for targeted protein degradation (TPD). Here, we report the discovery of the first generation of PDEδ autophagic degraders using an ATTEC approach. The most promising compound exhibited potent PDEδ binding affinity and efficiently induced PDEδ degradation in a concentration-dependent manner. Mechanistic studies confirmed that compound reduced the PDEδ protein level through lysosome-mediated autophagy without affecting the PDEδ mRNA expression. Importantly, compound was much more effective in suppressing the growth in KRAS mutant pancreatic cancer cells than the corresponding PDEδ inhibitor. Taken together, this study expands the application scope of the ATTEC approach and highlights the effectiveness of the PDEδ autophagic degradation strategy in antitumor drug discovery.
自噬栓系化合物(ATTEC)技术已成为一种有前景的靶向蛋白质降解(TPD)策略。在此,我们报告了使用ATTEC方法发现的第一代PDEδ自噬降解剂。最有前景的化合物表现出强大的PDEδ结合亲和力,并以浓度依赖性方式有效诱导PDEδ降解。机制研究证实,该化合物通过溶酶体介导的自噬降低了PDEδ蛋白水平,而不影响PDEδ mRNA表达。重要的是,该化合物在抑制KRAS突变型胰腺癌细胞生长方面比相应的PDEδ抑制剂更有效。综上所述,本研究扩展了ATTEC方法的应用范围,并突出了PDEδ自噬降解策略在抗肿瘤药物发现中的有效性。